A detailed history of Texas Yale Capital Corp. transactions in Astrazeneca PLC stock. As of the latest transaction made, Texas Yale Capital Corp. holds 13,478 shares of AZN stock, worth $884,561. This represents 0.05% of its overall portfolio holdings.

Number of Shares
13,478
Previous 13,178 2.28%
Holding current value
$884,561
Previous $1.03 Million 2.24%
% of portfolio
0.05%
Previous 0.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$76.67 - $87.62 $23,001 - $26,286
300 Added 2.28%
13,478 $1.05 Million
Q1 2024

May 08, 2024

BUY
$61.03 - $69.57 $22,947 - $26,158
376 Added 2.94%
13,178 $892,000
Q4 2023

Feb 13, 2024

BUY
$61.89 - $69.28 $9,716 - $10,876
157 Added 1.24%
12,802 $862,000
Q3 2023

Nov 09, 2023

SELL
$64.85 - $71.7 $95,977 - $106,116
-1,480 Reduced 10.48%
12,645 $856,000
Q3 2022

Nov 08, 2022

BUY
$53.02 - $135.75 $53,550 - $137,107
1,010 Added 7.7%
14,125 $775,000
Q1 2021

May 12, 2021

SELL
$47.16 - $54.44 $207,503 - $239,536
-4,400 Reduced 25.12%
13,115 $652,000
Q4 2020

Feb 10, 2021

BUY
$48.52 - $58.02 $9,704 - $11,604
200 Added 1.16%
17,515 $876,000
Q3 2020

Nov 10, 2020

BUY
$53.07 - $61.1 $5,307 - $6,110
100 Added 0.58%
17,315 $949,000
Q2 2019

Jul 24, 2019

SELL
$37.28 - $41.68 $641,775 - $717,521
-17,215 Reduced 50.0%
17,215 $711,000
Q1 2019

May 10, 2019

BUY
$35.49 - $43.02 $610,960 - $740,589
17,215 Added 100.0%
34,430 $1.39 Million
Q1 2018

May 03, 2018

SELL
$32.97 - $36.63 $12,034 - $13,369
-365 Reduced 2.08%
17,215 $602,000
Q4 2017

Feb 07, 2018

BUY
$32.09 - $34.78 $146,972 - $159,292
4,580 Added 35.23%
17,580 $610,000
Q3 2017

Nov 08, 2017

BUY
$28.96 - $34.0 $376,480 - $442,000
13,000
13,000 $440,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $203B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Texas Yale Capital Corp. Portfolio

Follow Texas Yale Capital Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Texas Yale Capital Corp., based on Form 13F filings with the SEC.

News

Stay updated on Texas Yale Capital Corp. with notifications on news.